PsyRx

Developing novel combination drug therapies that enhance existing antidepressants through carefully calibrated low-dose active compounds.

Health Tech & Life Sciences
Active
Seed Rishon LeZion, Israel Founded 2019
Last updated 2026-07-20
Total raised
$3.1M
Last: Undisclosed Round 2023-07
Stage
Seed
Founded
2019
Headcount
7
HQ
Rishon LeZion, Israel
Sector
Health Tech & Life Sciences

About

PsyRx is an Israeli biopharma company developing innovative combination drugs to address mental health challenges, particularly treatment-resistant depression. Their technology focuses on combining existing SSRI antidepressants with micro-doses of psychoactive substances like ibogaine and psilocybin, aiming for faster therapeutic onset, improved response, and reduced side effects without causing a psychedelic experience. The company also produces pharmaceutical-grade active compounds from natural sources using a proprietary agro-medical bioreactor platform. PsyRX CNS Bio-Tech Ltd, formerly Cannabotech LTD, engages in developing cannabinoid-based medication and healthcare products, including personalized cannabinoid-based products and CBD-based skincare and food-supplement products.

Funding history · 5 rounds · $3.1M total

2026-02
PIPE $1.1M
2025-10
Reverse Merger Undisclosed
2023-06
A Round Undisclosed
2022-07
Seed $550K
2020-11
Pre-Seed $1.5M

Headcount over time

From 4 (2021-07) to 5 (2025-10) · +1 (+25%) · 12 points · source: Finder history + radar grounding
70 2021-07 2025-10

Q&A

What is PsyRx's primary focus in drug development?
PsyRx is a pharmaceutical R&D company focused on developing biological API psilocybin and ibogaine using biological bioreactor technology, aiming to become a leading producer of GMP-standard versions of these compounds.
What is PsyRx's vision for a new antidepressant drug?
PsyRx aims to develop a revolutionary antidepressant drug that combines ibogaine with existing approved antidepressants, with the goal of reducing side effects and improving efficacy for the treatment of depression and addiction.
When was PsyRx founded?
PsyRx was founded in October 2019.
What is the total amount of funding PsyRx has raised to date?
PsyRx has raised a total of $2,380,000 USD.
When was PsyRx's most recent funding round?
PsyRx's most recent funding round occurred in July 2023, raising $330,000 USD.
Who are the co-founders of PsyRx?
The co-founders of PsyRx include Asher Holzer, Itay Hecht, and Kobi Buxdorf.
What is PsyRx's current product stage?
PsyRx's product is currently in the clinical trial stage.

Team · 3

Kobi Buxdorf
Founder · Co-founder, Board Member, CTO
Asher Holtzer
Founder · Co-founder, Board Member
Itay Hecht
Founder · Co-founder, CEO & Director

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsHerbals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

mental-healthpharma-companiestreatmentspharmaceuticalsfood-industrydrug-development
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitepsyrx.co/
LinkedInlinkedin.com/company/79826212
Facebookfacebook.com/psyrxpsychedelics

Identifiers & details

Legal namePsyRX CNS Bio-Tech Ltd
Founded2019
Employees (exact)7

Radar intelligence

Patents

EPO2

Web history (Wayback)

Domainpsyrx.co

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516095668
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2019-10-23
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens1
Registry events4 — shares_capital (1), annual_report (1), charge (1), people (1)
Registered addressז'בוטינסקי 31 חולון

Recent registry events

DateEvent
2025-11-27העברת מניות
2025-09-25דו~ח שנתי
2025-08-05רישום שעבוד
2026-03-01עדכון דירקטורים-הסרת דירקטור